Immunotec Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Dorion-vaudreuil Canada (1996)
Status: No NME R&D (1996)

Organization Overview

First Clinical Trial
2009
NCT00935610
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Immunotec Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

cow milk (3 trials)

whey protein (4 trials)

Drugs in Phase 2 Trials (1)

oryza sativa (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autism Spectrum Disorder (Phase 2)

Autistic Disorder (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Sarcopenia (Phase 2)

Weight Loss (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 3